Cytosorbents Crp (CTSO) - Total Assets
Based on the latest financial reports, Cytosorbents Crp (CTSO) holds total assets worth $45.75 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Cytosorbents Crp shareholders equity for net asset value and shareholders' equity analysis.
Cytosorbents Crp - Total Assets Trend (2004–2024)
This chart illustrates how Cytosorbents Crp's total assets have evolved over time, based on quarterly financial data.
Cytosorbents Crp - Asset Composition Analysis
Current Asset Composition (December 2024)
Cytosorbents Crp's total assets of $45.75 Million consist of 45.6% current assets and 54.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.9% |
| Accounts Receivable | $7.32 Million | 15.5% |
| Inventory | $2.73 Million | 5.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.75 Million | 7.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Cytosorbents Crp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cytosorbents Crp (CTSO) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cytosorbents Crp's current assets represent 45.6% of total assets in 2024, an increase from 33.3% in 2004.
- Cash Position: Cash and equivalents constituted 6.9% of total assets in 2024, down from 33.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 15.5% of total assets.
Cytosorbents Crp Competitors by Total Assets
Key competitors of Cytosorbents Crp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
China | CN¥5.70 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
MODULIGHT OY EO 1
F:78W
|
Germany | €49.14 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Nova EYE Medical Ltd
AU:EYE
|
Australia | AU$23.67 Million |
Cytosorbents Crp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.11 | 1.97 | 8.12 |
| Quick Ratio | 1.71 | 1.58 | 7.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $11.20 Million | $8.17 Million | $72.30 Million |
Cytosorbents Crp - Advanced Valuation Insights
This section examines the relationship between Cytosorbents Crp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.05 |
| Latest Market Cap to Assets Ratio | 0.81 |
| Asset Growth Rate (YoY) | -11.1% |
| Total Assets | $47.37 Million |
| Market Capitalization | $38.58 Million USD |
Valuation Analysis
Near Book Valuation: The market values Cytosorbents Crp's assets close to their book value (0.81x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Cytosorbents Crp's assets decreased by 11.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cytosorbents Crp (2004–2024)
The table below shows the annual total assets of Cytosorbents Crp from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $47.37 Million | -11.06% |
| 2023-12-31 | $53.26 Million | -15.77% |
| 2022-12-31 | $63.23 Million | -29.37% |
| 2021-12-31 | $89.52 Million | -0.48% |
| 2020-12-31 | $89.95 Million | +228.49% |
| 2019-12-31 | $27.38 Million | -16.38% |
| 2018-12-31 | $32.75 Million | +35.86% |
| 2017-12-31 | $24.10 Million | +148.65% |
| 2016-12-31 | $9.69 Million | -13.87% |
| 2015-12-31 | $11.25 Million | +32.89% |
| 2014-12-31 | $8.47 Million | +109.33% |
| 2013-12-31 | $4.05 Million | +21.15% |
| 2012-12-31 | $3.34 Million | +57.33% |
| 2011-12-31 | $2.12 Million | +17.14% |
| 2010-12-31 | $1.81 Million | -19.06% |
| 2009-12-31 | $2.24 Million | -33.91% |
| 2008-12-31 | $3.39 Million | +322.04% |
| 2007-12-31 | $802.57K | -76.70% |
| 2006-12-31 | $3.45 Million | +17991.84% |
| 2005-12-31 | $19.04K | -36.53% |
| 2004-12-31 | $30.00K | -- |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflamm… Read more